Patent details

Basic Information

Publication number:

EP2582714

PCT Application Number:

EP2011003074

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP117274019

PCT Publication Number:

WO2011160827

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

NOVEL JNK INHIBITOR MOLECULES

French Title of Invention:

NOUVEAUX INHIBITEURS DE JNK

German Title of Invention:

NEUE JNK-HEMMER

SPC Number:

Dates

Filing date:

21/06/2011

Grant date:

10/05/2017

EP Publication Date:

24/04/2013

PCT Publication Date:

29/12/2011

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

10/05/2017

EP B1 Publication Date:

10/05/2017

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

21/06/2019

Expiration date:

21/06/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

10/05/2017

 

 

Name:

Xigen Inflammation Ltd.

Address:

Arch. Makariou III 195 Neocleous House, 3030 Limassol, Cyprus (CY)

Agent

Name:

Office FREYLINGER S.A.

From:

12/07/2017

Address:

PO Box 48, 8001, STRASSEN, Luxembourg (LU)

To:

Inventor

Name:

BONNY, Christophe

Address:

Switzerland (CH)

Priority

Priority Number:

PCT/EP2010/003729

Priority Date:

21/06/2010

Priority Country:

World Intellectual Property Office (WIPO) (WO)

Classification

IPC classification:

C07K 7/06; C07K 14/47; G01N 33/53;

Publication

European Patent Bulletin

Issue number:

201719

Publication date:

10/05/2017

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

22/10/2018

Last Annual Fee Paid Number:

8

Last Annual Fee Paid Amount:

99 Euro

Payer:

PAVIS GMBH

Filing date	Document type	Number of pages
19/07/2017	Outgoing Correspondence	1
12/07/2017	Power Of Attorney	1